The UPMC Enterprises-backed mental health tool provider had raised more than $21m but is shuttering after failing to secure an acquisition.

Merck & Co, Celgene, Amgen and Eli Lilly all took part in an $85.4m round that boosted the cancer drug developer's total funding to more than $175m.

Click has secured financing in a round led by Sanofi Ventures as it develops digital medicines for conditions including depression, insomnia and chronic pain.

The nanopore sequencing platform developer has closed a $15.5m series 3 round backed by Tsingyuan Ventures.

The Tasly-backed hepatitis C drug developer priced its shares in the middle of their range and is set to float at the start of next month.

Duke University spinout Cereius has signed up BioInnovation Capital to its series A round as it looks to commercialise a radiotherapeutic approach for brain tumours.

Viz.ai, developer of a system that helps detect strokes, got the money in a Kleiner Perkins Caufield & Byers-led series A round backed by GV.

Upwards of 17 investors, including AbbVie, Eli Lilly, Alphabet, Merck & Co and Amgen, backed the neurodegenerative disease drug developer's series E round.